move beyond the one-size-fits-all supplement model. The company operates across three channels: a direct-to-consumer personalized probiotic platform (flore.com), a B2B clinical provider channel serving practitioners (Flore Clinical), and a premade consumer product line, Real Good Ones. This tiered architecture is unified by a shared microbiome data spine, allowing customers to move from off-the-shelf products into fully personalized, sequencing-driven formulations. Flore's approach is grounded in real-world evidence from a longitudinal dataset spanning tens of thousands of subjects, and the company is actively advancing clinical research, including a bacteriophage intervention study in autism spectrum disorder in collaboration with academic investigators. Flore is led by CEO and co-founder Craig Rouskey and COO and co-founder Megan Crocker.